Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic treatment trial for autonomous cortisol secretion to identify candidates for adrenalectomy
2022-002241-18Phase 4Active
- Sponsor
- Helse Bergen
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of metyrapone in Mild hypercortisolism (SCS), sponsored by Helse Bergen. Primary endpoint: Biochemical response of autonomous cortisol secretion. Started Nov 2022; status: active.
02
Drugs
metyrapone
03
Conditions
Mild hypercortisolism (SCS)
Beyond the preview
Go deeper on 2022-002241-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002241-18.